FDA pushes Leqembi subcutaneous decision to Aug. 24; Artiva secures $300M and Pharvaris sets pricing
The U.S. Food and Drug Administration has postponed its review of the subcutaneous formulation of Leqembi. The original target date earlier this month has been moved to August 24, as Biogen and Eisai indicated the agency requested additional information.
Biogen partner Artiva Therapeutics announced it has raised $300 million to support further development of its rheumatoid arthritis data program. The funding round underscores investor confidence in the company's pipeline.
Pharvaris announced pricing for its latest offering, detailing the price points for the new product. The company said the pricing reflects the therapeutic value and market positioning of the drug.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “FDA delays Leqembi decision; Artiva raises $300M; Pharvaris prices offering”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that